ARTICLE | Clinical News
Allos reports lymphoma data
May 16, 2008 12:23 AM UTC
Allos (NASDAQ:ALTH) said interim data from the pivotal Phase II PROPEL trial of pralatrexate ( PDX) to treat relapsed or refractory peripheral T cell lymphoma (PTCL) showed that 19 of 65 evaluable pat...